Profile data is unavailable for this security.
About the company
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The Company's products are mainly applied in the treatment of metabolism and digestive tract system, cardiovascular system, central nervous system, blood system, anti-tumor and anti-infection diseases. The Company is also engaged in medical equipment and medical diagnosis business, as well as the provision of medical services. It distributes its products primarily in domestic and overseas markets.
- Revenue in HKD (TTM)44.50bn
- Net income in HKD2.59bn
- Incorporated1995
- Employees40.37k
- LocationShanghai Fosun Pharmaceutical Group Co LtdBuilding A, No. 1289 Yishan RoadSHANGHAI 200233ChinaCHN
- Phone+86 2 133987870
- Fax+86 2 133987871
- Websitehttps://www.fosunpharma.com/
More ▼
Mergers & acquisitions
| Acquired company | 600196:SHH since announced | Transaction value |
|---|---|---|
| Shanghai Rehabilitation Equity Investment Fund Management Co Ltd | -11.86% | 3.04m |
| Suzhou Xingchen Venture Capital Partnership LP | -19.38% | 412.00k |
| Shining Star (Tianjin) Investment Management Partnership LP | -19.38% | 206.00k |
Data delayed at least 15 minutes, as of Mar 13 2024 07:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sichuan Kelun-Biotech Biophrmctcl Co Ltd | 1.66bn | -619.37m | 38.14bn | 1.42k | -- | 15.18 | -- | 22.95 | -2.79 | -2.79 | 7.58 | 11.46 | -- | -- | -- | 1,174,458.00 | -- | -- | -- | -- | 49.28 | -- | -37.27 | -- | 2.47 | -34.90 | 0.0251 | -- | 91.62 | -- | 6.81 | -- | -- | -- |
| Akeso Inc | 4.88bn | 2.19bn | 42.43bn | 2.78k | 18.75 | 8.14 | 18.86 | 8.69 | 2.61 | 2.61 | 5.83 | 6.02 | 0.6168 | 0.3749 | 15.98 | 1,757,684.00 | 26.47 | -11.59 | 31.40 | -13.87 | 96.96 | -- | 42.91 | -42.49 | 4.39 | 19.18 | 0.3983 | -- | 440.35 | 337.43 | 273.60 | -- | 63.99 | -- |
| Sino Biopharmaceutical Ltd | 28.26bn | 1.99bn | 54.34bn | 25.81k | 26.89 | 1.61 | 8.96 | 1.92 | 0.1075 | 0.1358 | 1.53 | 1.79 | 0.4104 | 2.31 | 5.73 | 1,095,229.00 | 7.23 | 13.11 | 13.37 | 21.74 | 80.95 | 80.37 | 17.61 | 27.47 | 0.9649 | 11.83 | 0.2479 | 25.02 | 0.6657 | 4.63 | -10.29 | -27.22 | -7.18 | 1.15 |
| Shanghai Fosun Pharmaceutical (Group) | 44.50bn | 2.59bn | 62.21bn | 40.37k | 13.12 | 0.6914 | 9.51 | 1.40 | 0.9709 | 0.9709 | 16.67 | 18.43 | 0.3741 | 3.00 | 5.36 | 1,102,259.00 | 2.64 | 4.32 | 4.37 | 7.02 | 47.65 | 50.53 | 7.05 | 10.70 | 0.7778 | -- | 0.3819 | 30.15 | -5.85 | 10.79 | -35.84 | -2.41 | 10.95 | -3.10 |
| WuXi Biologics (Cayman) Inc | 18.38bn | 3.67bn | 63.29bn | 12.74k | 17.62 | 1.45 | 11.84 | 3.44 | 0.8433 | 0.8433 | 4.23 | 10.26 | 0.321 | 5.04 | 3.02 | 1,442,408.00 | 6.73 | 8.28 | 8.47 | 10.25 | 40.08 | 43.25 | 20.96 | 27.46 | 2.54 | -- | 0.0939 | 0.00 | 11.56 | 46.38 | -23.09 | 40.07 | 20.32 | -- |
| Innovent Biologics Inc | 6.70bn | -1.11bn | 65.72bn | 4.87k | -- | 4.86 | -- | 9.82 | -0.7031 | -0.7031 | 4.29 | 8.33 | 0.3248 | 0.9481 | 7.85 | 1,374,180.00 | -5.38 | -13.06 | -6.80 | -15.85 | 81.69 | 84.51 | -16.56 | -43.44 | 2.78 | -162.51 | 0.2242 | -- | 36.21 | 265.79 | 52.83 | -- | 34.60 | -- |
| CSPC Pharmaceutical Group Ltd | 33.93bn | 6.34bn | 80.84bn | 23.50k | 12.71 | 2.25 | 10.43 | 2.38 | 0.5336 | 0.5336 | 2.86 | 3.01 | 0.7144 | 3.26 | 6.21 | 1,443,739.00 | 13.79 | 16.08 | 18.50 | 21.57 | 70.51 | 72.95 | 19.31 | 19.63 | 2.32 | -- | 0.0198 | 35.51 | 1.66 | 12.16 | -3.58 | 13.77 | -2.58 | 25.33 |
Data as of May 07 2024. Currency figures normalised to Shanghai Fosun Pharmaceutical Group Co Ltd's reporting currency: Hong Kong Dollar HKD
12.27%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 05 Apr 2024 | 22.25m | 4.03% |
| Martin Currie Investment Management Ltd.as of 31 Mar 2024 | 12.80m | 2.32% |
| BlackRock Fund Advisorsas of 25 Apr 2024 | 8.36m | 1.52% |
| BlackRock Advisors (UK) Ltd.as of 25 Apr 2024 | 6.08m | 1.10% |
| EARNEST Partners LLCas of 31 Mar 2024 | 3.88m | 0.70% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2022 | 3.87m | 0.70% |
| Geode Capital Management LLCas of 02 May 2024 | 2.85m | 0.52% |
| Wilmington Trust Investment Management LLCas of 31 Dec 2022 | 2.59m | 0.47% |
| Nomura Asset Management Co., Ltd.as of 29 Mar 2024 | 2.57m | 0.47% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 2.47m | 0.45% |
More ▼
Data from 31 Dec 2023 - 02 May 2024Source: FactSet Research Systems Inc.
